Evidence map›Paper›PMID 36919063›Full record

ArticleCureus2023

Thymoma and Myasthenia Gravis: An Examination of a Paraneoplastic Manifestation.

Mira Itani, Yarden Goldman Gollan, Kristin Ezell, Mohamed Mohanna, Saad Sabbagh, Caoimhin Mears, Katrina A Mears, Barbara Dominguez, Doron Feinsilber, Zeina Nahleh

Open access · diamondFull text readCase Reports
In one paragraph

Article in Cureus, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. High risk of hypoxemic COVID-19 pneumonia in myasthenia gravis patients with type I IFN autoantibodies.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Mira ItaniHematology-Oncology, Cleveland Clinic Foundation, Weston, USA.
Yarden Goldman GollanHemaology-Oncology, Ross University School of Medicine, Weston, USA.
Kristin EzellHematology-Oncology, Ross University School of Medicine, Weston, USA.
Mohamed MohannaHematology-Oncology, Cleveland Clinic Florida, Weston, USA.
Saad SabbaghHematology-Oncology, Cleveland Clinic Florida, Weston, USA.
Caoimhin MearsOphthalmology, Retina Consultants of Southwest Florida, Fort Myers, USA.
Katrina A MearsOphthalmology, Retina Consultants of Southwest Florida, Fort Myers, USA.
Barbara DominguezHematology-Oncology, Cleveland Clinic Florida, Weston, USA.
Doron FeinsilberHematology-Oncology, Cleveland Clinic Florida, Weston, USA.
Zeina NahlehHematology-Oncology, Cleveland Clinic Florida, Weston, USA.
Cleveland Clinic Florida · USCleveland Clinic · USRetina Consultants of Houston · USUniversity of the West · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Thymoma is a rare type of malignancy but is considered one of the most common neoplasms that occur in the anterior mediastinum. A large proportion of thymomas are associated with paraneoplastic syndromes, such as myasthenia gravis. Whenever feasible, the standard of care for the treatment of thymoma should focus on the control of paraneoplastic syndromes, surgical resection, and adjuvant therapy if appropriate. A 36-year-old female patient with a significant past medical history of obesity and iron deficiency anemia who underwenten bloc resection of thymoma three months prior now presented to the benign hematology clinic to establish care for the management of anemia. Upon review of systems, the patient incidentally reported fatigue, weakness with repetitive motion, occasional blurred vision, headaches, and exertional dyspnea. Physical examination was positive for horizontal nystagmus. Given the patient's history and clinical findings, suspicion of myasthenia gravis was high. Further work-up demonstrated anti-acetylcholine receptor titers of 5.70 nmol/L (normal < 0.21 nmol/L), supporting a diagnosis of myasthenia gravis in this patient. She was subsequently started on pyridostigmine. Often, patients with thymoma experience paraneoplastic syndrome-related symptoms prior to thymectomy, and in many cases thymectomy is curative. However, in the case presented, we examine a patient that was asymptomatic prior to surgery and subsequently reported the onset of symptoms following what we suspect was an exacerbation due to general anesthesia and pain control medications. We argue that all patients with thymoma should undergo systematic evaluation and treatment of paraneoplastic syndromes, regardless of clinical symptoms and prior to surgery, in order to improve patient quality of life and hospital outcomes.

Indexed as

case reportmyasthenia gravis (mg)neurologyoncologyparaneoplastic syndromethoracic surgerythymoma

Identifiers

PMID36919063
PMCPMC10008435
OpenAlexW4319963769

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read8
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.